Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Theratechnologies Inc > JP Morgan
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(290)
•••
Post by scarlet1967on Jan 04, 2024 10:44am
282 Views
Post# 35810415

JP Morgan

JP Morgan A " potential partner" for their R&D programs is well overdue! One can only hope that their NASH asset get monetized after all this long wait. As for oncology they have said previously( the last announced plan)they will complete the part 3 of the phase1 and funding for the rest of the trial if and when they get there will be by a potential partnership. On a different note they have 4 job openings for HIV therapeutic specialists in various regions!
They are either reinforcing the sale team and/or replacing the underperforming team members which is in my opinion a must to do in order to boost the sales.
https://www.linkedin.com/posts/theratechnologies-inc_jpmorgan-jpm24-jpmhc24-activity-7148689571222888449-4U8i?utm_source=share&utm_medium=member_ios

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities